Orica-GreenEdge admits fault on drug test

A rider from Australia's Orica-GreenEdge cycling team has tested positive to a drug found in an asthma inhaler.

British rider Simon Yates

Cycling team Orica-GreenEDGE is taking the blame after one of its riders failed a doping test. (AAP)

British cyclist Simon Yates has not been suspended and his Orica-GreenEdge team have taken the full blame for a doctor's error which led to a positive drugs test.

Yates tested positive to terbutaline, which is used to relieve asthma symptoms.

The Australian team said an administrative error led to the medicine being administered without the required therapeutic use exemption certificate.

Cycling's governing body the UCI on Friday said Yates has not been provisionally suspended due to the nature of the substance involved.

"The Union Cycliste Internationale (UCI) confirms that British rider Simon Yates has been notified of an adverse analytical finding of terbutaline in a sample collected in the scope of an in-competition control on March 12, 2016," it said.

"As per the UCI's anti-doping rules, such substance does not entail the imposition of a provisional suspension.

"The rider has the right to request and attend the analysis of the B sample.

"At this stage of the procedure, the UCI won't comment any further."

Orica-GreenEdge say they are attempting to clarify the situation with the UCI.

"There has been no wrongdoing on Simon Yates' part," said an Orica GreenEdge statement.

"The team takes full responsibility for this mistake and wishes to underline their support for Simon during this process."

The team were made aware of the positive test on April 22, at stage six of Paris-Nice. He finished sixth on the stage.

The statement added: "The substance was given to Simon Yates in the form an asthma inhaler and accordingly, this was noted by the team doctor on the doping control form, signed at the time of the test.

"The substance was given in an ongoing treatment of Simon Yates' documented asthma problems. However, in this case the team doctor made an administrative error by failing to apply for the TUE required for the use of this treatment.

"The use of terbutaline without a current TUE is the reason it has been flagged as an adverse analytical finding.

"This is solely based on a human error that the doctor in question has taken full responsibility for."


Share

2 min read

Published

Source: AAP



Share this with family and friends


Get SBS News daily and direct to your Inbox

Sign up now for the latest news from Australia and around the world direct to your inbox.

By subscribing, you agree to SBS’s terms of service and privacy policy including receiving email updates from SBS.

Download our apps
SBS News
SBS Audio
SBS On Demand

Listen to our podcasts
An overview of the day's top stories from SBS News
Interviews and feature reports from SBS News
Your daily ten minute finance and business news wrap with SBS Finance Editor Ricardo Gonçalves.
A daily five minute news wrap for English learners and people with disability
Get the latest with our News podcasts on your favourite podcast apps.

Watch on SBS
SBS World News

SBS World News

Take a global view with Australia's most comprehensive world news service
Watch the latest news videos from Australia and across the world